Cambridge Isotope Laboratories Invests In Future Growth With New Land Purchase In Xenia, Ohio

Cambridge Isotope Laboratories, Inc. (CIL), a leading figure in the stable isotopes and stable isotope-labeled compounds industry, has recently expanded its operational footprint with the acquisition of an additional 14.8 acres of land at its Cambridge Isotope Separations (CIS) facility in Xenia, Ohio. This strategic move, as articulated by Mike Steiger, Vice President of Engineering and Project Execution for CIL, is aimed at facilitating easier access to utilities for future expansions, marking a significant step in the company's growth trajectory.

The newly acquired land is located to the west of a 20-acre parcel purchased in 2017, which currently hosts the North Star expansion project. This project, now in the startup phase, has been highlighted as a major leap forward in the production of 13C isotopes, positioning North Star as the largest 13C separation facility globally. This expansion is set to substantially boost CIL's production capacity, ensuring enhanced reliability for customers dependent on this stable isotope.

Cliff Caldwell, CEO of CIL, emphasized the acquisition's role in reinforcing CIL's commitment to innovation and customer-centric growth. He noted that CIL's collaborative efforts with its global customer base are focused on developing and commercializing high-value applications for isotopically labeled compounds. The availability of additional land ensures that CIL can meet growing demands and support technological advancements in various applications worldwide.

The CIS facility is not only renowned for its 13C separation capabilities but also stands as one of the largest 18O isotope-separation facilities globally and houses the world's most extensive commercial D2O re-enrichment columns. The importance of stable isotopes like deuterium has surged across several high-technology fields, including pharmaceuticals, semiconductors, and flat panel displays. To maintain a reliable supply chain, CIL has secured a three-year supply contract with a Canadian source for D2O and maintains an 18–24-month supply at four of its locations.

About Cambridge Isotope Laboratories, Inc.: As the world's largest manufacturer and global supplier of stable isotopes and stable isotope-labeled compounds, CIL serves a diverse range of markets including research, environmental studies, neonatal screening, pharmaceuticals, medical diagnostics, OLED technology, and industrial applications. With subsidiaries such as ABX in Dresden, Germany focusing on radioisotopic-labeled compounds for cancer diagnosis and treatment, CIL demonstrates its broad expertise and commitment to advancing scientific and medical research. Owned by Otsuka Pharmaceutical, CIL operates from multiple locations across the globe including two facilities in Boston, Massachusetts; Xenia, Ohio; China; Canada; Dresden, Germany; and Saclay, France. For more information on Cambridge Isotope Laboratories' offerings and initiatives, visit their website at isotope.com.